Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin’s lymphoma - 17/02/10
, B. Delmas-Marsalet a, S.C. Misra a, A. Ulusakarya a, Y. Gumus a, N. Frénoy b, C. Guettier c, R. Saffroy b, P. Innominato a, W. Almohamad a, N. Brahimi a, M. Haydar a, E. Goldschmidt a
Corresponding author. Département de cancérologie, hôpital Paul-Brousse, 12-14, avenue Paul-Vaillant-Couturier, 94804 Villejuif, France.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 5 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Background |
We explored the addition of rituximab to high-dose cytarabine (ara-C), oxaliplatin (L-OHP), and dexamethasone [R-DHAOx], in resistant and relapsed patients with CD20-positive follicular non-Hodgkin’s lymphoma.
Methods |
Twenty-two patients were included; they were treated previously with one to five chemotherapy regimens, including 13 patients who had also received rituximab. R-DHAOx consisted of rituximab, 375mg/m2, day 1; dexamethasone, 40mg/d, days one to four; L-OHP, 130mg/m2, day 1; and ara-C, 2000mg/m2 every 12 h, day 2. Courses were repeated every 21 days for eight courses.
Results |
Twenty-one patients (95%) achieved a complete response and one had a partial response. Responses were obtained in patients with and without resistance to prior treatment, either alone or combined with rituximab. The median follow-up time was 58.3 months (range, 8.7–92.6 months). Progression-free survival reached a plateau at 84% at 38.2 months. Only two of the 21 complete responders have relapsed. Tumor molecular markers disappeared in all 10 complete responders whose markers were found before treatment. Peripheral neuropathy related to the cumulative dose of L-OHP, and myelosuppression were the most prominent toxic effects.
Conclusions |
R-DHAOx is highly active for salvage treatment of patients with follicular non-Hodgkin’s lymphoma, and it produces long-term antitumor efficacy.
Le texte complet de cet article est disponible en PDF.Keywords : Cytarabine, Follicular non-Hodgkin’s lymphoma, Molecular tumor markers, Oxaliplatin, Rituximab, Salvage therapy
Plan
Vol 64 - N° 2
P. 83-87 - février 2010 Retour au numéro
Article précédent
- Editorial Board
- Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects
- Hua Shen, Yuan Yuan, Jing Sun, Wen Gao, Yong-Qian Shu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?